Revolune Launches Multiplex Immunofluorescence Reagents

On June 15, 2026, Revolune announced the commercial availability of its multiplex immunofluorescence reagents, marking a significant transition from their early access phase to broader market deployment. The company's reagents are designed to support scalable and reproducible spatial biology workflows, crucial for advancing translational research, biopharmaceutical applications, and biomarker discovery.

Addressing challenges faced by researchers—such as complex assays and lengthy protocols—Revolune aims to make multiplex immunofluorescence accessible for routine lab use. The reagent platform enables visualization of multiple protein biomarkers in intact tissues, facilitating more efficient laboratory operations.

This commercial rollout builds on the early access program feedback from over 30 laboratories. Revolune's initial offerings target applications in oncology, translational medicine, and biomarker development. Adrian Arechiga, the newly appointed Chief Commercial Officer, will lead the commercial strategy to promote global adoption.